Good news in the fight against cancer!
This Tuesday, Moderna and Merck confirmed that Phase 2b of the combination of a drug from the Merck laboratory with Moderna's messenger RNA system in a vaccine would significantly reduce skin cancer, specifically melanoma.
But be patient: Phase 3 testing is still needed as well as additional studies.
The explanation, in the note of the day.